**ORIGINAL ARTICLE**

**6′-O-galloylpaeoniflorin alleviates inflammation and oxidative stress in pediatric pneumonia through activating Nrf2 activation**

Cheng Xu*, Lei Song, Weiyang Zhang, Rong Zou, Meijun Zhu

Department of Pediatrics, Nantong First People's Hospital (The Second Affiliated Hospital of Nantong University), Nantong, Jiangsu Province, China

Received 31 March 2022; Accepted 20 April 2022

Available online: 1 July 2022

**KEYWORDS**

LPS; Nrf2; oxidative stress; pediatric pneumonia; 6′-o-galloylpaeoniflorin (GPF)

**Abstract**

Objective: To assess the therapeutic effect and mechanism of 6′-o-galloylpaeoniflorin (GPF) in pediatric pneumonia.

Methods: The effects of lipopolysaccharide (LPS) and GPF on cell viability and apoptosis were examined by cell counting kit-8 assay and flow cytometry analysis. The oxidative stress and inflammatory response were assessed by detecting expression levels of superoxide dismutase, glutathione, r-glutamyl cysteingle-glycine, myeloperoxidase, and malondialdehyde as well as tumor necrosis factor-α, Interleukin-18, and Interleukin-10 by using enzyme-linked-immunosorbent serologic assay. Moreover, the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) pathway was detected by immunoblot assay, and the influence of Nrf2-knockdown on cell viability, oxidative stress, and inflammation response was also investigated.

Results: The results established that GPF increased the viability of LPS-induced pneumonia cells. In addition, GPF reduced LPS-induced oxidative stress in pneumonia cells. It was further discovered that GPF reduced LPS-induced inflammation in pneumonia cells. GPF improved the activity of Nrf2 in LPS-treated pneumonia cells, and therefore alleviated inflammation and oxidative stress in pediatric pneumonia.

Conclusion: GPF could serve as a promising drug for treating pediatric pneumonia.

© 2022 Codon Publications. Published by Codon Publications.

**Introduction**

The World Health Organization has estimated that there are 150.7 million cases of lung infections in children aged less than 5 years with lung infections, with which as many as 20 million patients require hospitalization.\(^1\) Pediatric pneumonia is one of the most common pediatric diseases leading to infant death. It is primarily caused by bacterial and viral infections and its primary clinical manifestations include dyspnea, fever, cough, and shortness of breath.\(^2,3\)

*Corresponding author: Cheng Xu, Department of Pediatrics, Nantong First People's Hospital (The Second Affiliated Hospital of Nantong University), No. 6 North Road, Child Lane, Chongchuan District, Nantong City, Jiangsu Province 226001, China. Email address: xucheng...dr@163.com

https://doi.org/10.15586/aei.v50i4.639
Copyright: Xu C, et al.
License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/
Pneumonia in children can result in lung tissue destruction, neutrophil infiltration, and release of pro-inflammatory cytokines such as tumor necrosis factor (TNF-α), interleukin (IL)-1β, and IL-6. Activated neutrophils aggravate inflammation and injury by producing reactive oxygen species (ROS) and proteolytic enzymes. Lipopolysaccharide (LPS) is the prime component of endotoxin, and is considered as the most important pathogen leading to lung inflammation and sepsis. LPS activates a large number of inflammatory cells and induces pneumonia through a variety of signaling pathways. Therefore, developing new drugs to combat pneumonia in children is urgently required.

Herbs such as Urtica dioica (stinging nettle) have exhibited beneficial anti-inflammatory functions. For example, comparison of the substrate specificities of endo-beta-N-acetylglucosaminidases from Streptomyces griseus and *Diplococcus pneumoniae* has been revised. The beneficial effects of *Urtica dioica* on the function, histology, and molecular changes in the hippocampus of streptozotocin (STZ)-induced diabetic mice have been reported. G6-O-galloylpaeoniflorin (GPF) is an acylated monoterprenoid glucoside compound extracted from the roots of peony plant (genus Paeonia). It is composed of d-glucose, benzoyl, and gallic parts, and has antitumor, antiplatelet aggregation, anticoagulant, and antiallergic potential, with ability to promote angiogenesis. In addition, it can alleviate inflammatory responses, cell damage, and apoptosis in vitro, and has free radical scavenging and antioxidant properties. GPF attenuates osteoclast generation and alleviates osteoporosis by inhibiting production of reactive oxygen species (ROS) and MAPKs/C-FOS/NFATc1 signaling pathway, and alleviates neuroinflammation and oxidative stress induced by cerebral ischemia-reperfusion through activating phosphoinositide 3-kinase (PI3K)/Akt strain transforming (Akt)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. GPF attenuates osteoclastogenesis and relieves osteoporosis via suppressing ROS generation and MAPKs/c-Fos/NFATc1 pathway. However, GPF has not been reported to relieve pneumonia in children.

In this study, pneumonia cell model was constructed by LPS stimulation. Our data demonstrated that GPF increased the activity of LPS-treated pneumonia cells. GPF reduced LPS-induced oxidative stress in pneumonia cells. In addition, GPF reduced LPS-induced inflammation in pneumonia cells. Mechanically, we found that GPF improved the activity of Nrf2 in LPS-treated pneumonia cells, and therefore alleviated inflammation and oxidative stress in pediatric pneumonia. We anticipated that GPF could serve as a promising drug for treating pediatric pneumonia.

**Materials and Methods**

**Cell culture**

Human bronchial epithelial (Beas-2B) cells (the Cell Resource Center of Peking Union Medical College, China) were incubated with RPMI-1640 medium (Gibco; Thermo Fisher Scientific Inc., Waltham, MA, USA) and 10% fetal bovine serum (FBS; Thermo Fisher Scientific Inc.) supplemented with 1% penicillin-streptomycin in a humidified culture hood with 5% CO2 at 37°C. The lung injury was achieved by LPS stimulation at a concentration of 5 µg/mL for 12 h at 37°C. Cells were stimulated with increasing dose of GPF. For Nrf2 knockdown, small interfering RNAs (siRNAs) targeting Nrf2 (si-Nrf2) (5'-CCGGCAUUUCUAAACACAATT-3') were generated by GenePharma (Shanghai, China) and transfected into Beas-2B cells with lipofectamine 3000 (Invitrogen, Carlsbad, CA) for 48 h.

**Cell Counting Kit-8 (CCK-8) assay**

For assessing cell viability, CCK-8 assay was performed. After indicated treatment, Beas-2B cells were added to 10-µL CCK-8 solution in each well. After incubation for 1 h at 37°C, absorbance in each well was determined at 450 nm using a microplate reader (R&d Systems, Minneapolis, MN) at 450 nm.

**Flow cytometry (FCM)**

Cells were placed into 96-well plate and treated as designed. Then the cells were fixed and labeled with 50-µg/mL propidium iodide (PI) at room temperature for 30 min in dark. Then stained cells were washed by centrifugation and resuspended, followed by analysis on BD FACS Canto™ II system (BD Biosciences, San Diego, California).

**Western blotting**

Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer. After collection of supernatant, protein concentration was determined by bicinchoninic (BCA) protein assay kit (Beyotime Biotechnology, Shanghai, China). Then, proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred onto polyvinylidene difluoride (PVDF) membranes. After that, membranes were incubated with 5% bovine serum albumin (BSA), followed by primary antibodies targeting Bcl-2 (1:1000, Abcam, Cambridge, UK), Bax (1:1000, Abcam), Nrf2 (1:1000, Abcam), NQO-1 (1:1000, Abcam), HO-1 (1:1000, Abcam), and β-actin (1:10000; Abcam). Membranes were maintained in horseradish peroxidase (HRP)-conjugated secondary antibodies at a dilution of 1:1000 for 2 h. The membranes were rinsed in tris buffered saline with tween (TBST) for 15 min before the signals were detected with Luminata Cresendo Western HRP substrate via Molecular Imager ChemiDoc XRS+ System (Bio-Rad, Philadelphia, PA).

**Detection of antioxidant activity**

Levels of superoxide dismutase (SOD), glutathione, r-glutamyl cysteineig + glycine (GSH), myeloperoxidase (MPO), and malondialdehyde (MDA) were measured using detection kits obtained from Nanjing Jiancheng Bio-Engineering Institute (Jiangsu, China) and following the manufacturer’s instructions.

**Enzyme-linked-immunosorbert serologic assay (ELISA)**

Concentrations of TNF-α, IL-18, and IL-10 in cell lysates were measured by ELISA kit following manufacturer’s protocols. Briefly, samples were added into wells, and biotin-conjugated
primary antibodies were placed prior to addition of avidin-conjugated HRP. Then, enzyme substrate was added for chromogenic reaction. Intensity of each well was measured using a microplate reader (R&D Systems). All experiments were conducted according to the stated guidelines.

Statistical analysis

Statistical analysis was conducted by unpaired two-tailed Student’s t-test using the SPSS software. Data were displayed as mean ± standard error of mean (SEM), and P < 0.05 was considered as significant difference.

Results

GPF could improve LPS-treated Beas-2B cell viability

The cell viability of Beas-2B cells in response to LPS and increasing concentration of GPF was examined. It was noted that cells stimulated by varying doses of GPF demonstrated no significant difference in cell viability, indicating that GPF had no toxicity in cell viability (Figures 1A and 1B). The cell viability was decreased in cells treated with GPF at a concentration of 160 µM (Figure 1B). The cell viability was also decreased post-stimulation with LPS. However, GPF treatment relieved cell viability in LPS-stimulated cells

Figure 1

GPF ameliorated oxidative stress induced by LPS

Lipopolysaccharide stimulation is believed to induce oxidative stress. Therefore, oxidative response in Beas-2B cells stimulated by LPS and GPF was evaluated. The expression of MDA and MPO was enhanced but that of SOD and GSH was reduced in LPS-stimulated cells (Figure 2). GPF treatment significantly reversed the effect of LPS on the expression of SOD, MDA, MPO, and GSH in a dose-dependent manner, indicating its antioxidant effects.

GPF reduced LPS-induced inflammation in pneumonic cells

In order to explore inflammatory response in LPS-treated cells, levels of IL-6, IL-1β, and TNF-α were monitored. LPS significantly increased the levels of IL-6, IL-1β, and TNF-α.
Bacterial infection is the fundamental cause of pneumonia in children. Therefore, it is important to thoroughly clarify the pathogenesis of pneumonia in children, carry out effective anti-inflammatory treatment, and develop effective clinical drugs to improve the cure rate of pneumonia in children. Up to now, although a large number of antibacterial/antiviral drugs have been developed for treating pediatric pneumonia, more of effective drugs are required to improve the therapeutic effect to combat pediatric pneumonia. Traditional Chinese medicine (TCM) has several advantages for treating pediatric pneumonia, as many TCM elements have been found to be suitable for the same.

In this study, we discovered that GPF alleviated inflammation and oxidative stress in pediatric pneumonia. We, therefore, believed that GPF could serve as a promising drug for treating pediatric pneumonia.

Lipopolysaccharide is the prime component of endotoxin and is considered as the most important pathogen resulting in lung inflammation and sepsis. LPS activates a large number of inflammatory cells and induces pneumonia through a variety of signaling pathways. In this study, we successfully constructed a pneumonia model using LPS, and confirmed the effects of GPF on this model.

Results of CCK-8 and FCM assays demonstrated that GPF increased the viability of LPS-induced pneumonia cells. ELISA demonstrated that GPF reduced LPS-induced oxidative stress and inflammation in pneumonia cells. The results confirmed that GPF could serve as a promising drug for treating pediatric pneumonia. Multiple biological activities of GPF have been unraveled in several types of diseases. GPF attenuated osteoclastogenesis as well as relieved osteoporosis by suppressing MAPKs/c-Fos/NFATc1 pathway. GPF regulated growth and metastasis of non-small cell lung cancer (NSCLS) by regulating the AMPK/miR-299-5p/ATF2 pathway. In addition, GPF could protect keratinocytes against oxidative stress-induced cell damage. Similarly, we also discovered that GPF suppressed oxidative stress in pediatric pneumonia. It could also reduce neuroinflammation and oxidative stress induced by cerebral ischemia-reperfusion through activating PI3K/Akt/Nrf2 pathway. Here, GPF also improved the activity of Nrf2 in LPS-treated pneumonia cells, and hence alleviated inflammation and oxidative stress in pediatric pneumonia. However, this precise mechanism requires further study.

Discussion

Pediatric pneumonia is one of the important causes of neonatal death with high morbidity and mortality. Bacterial infection is the fundamental cause of pneumonia in children. Therefore, it is important to thoroughly clarify the pathogenesis of pneumonia in children, carry out effective anti-inflammatory treatment, and develop effective clinical drugs to improve the cure rate of pneumonia in children. Up to now, although a large number of antibacterial/antiviral drugs have been developed for treating pediatric pneumonia, more of effective drugs are required to improve the therapeutic effect to combat pediatric pneumonia. Traditional Chinese medicine (TCM) has several advantages for treating pediatric pneumonia, as many TCM elements have been found to be suitable for the same. In this study, we discovered that GPF alleviated inflammation and oxidative stress in pediatric pneumonia. We, therefore, believed that GPF could serve as a promising drug for treating pediatric pneumonia.

Lipopolysaccharide is the prime component of endotoxin and is considered as the most important pathogen resulting in lung inflammation and sepsis. LPS activates a large number of inflammatory cells and induces pneumonia through a variety of signaling pathways. In this study, we successfully constructed a pneumonia model using LPS, and confirmed the effects of GPF on this model.

Results of CCK-8 and FCM assays demonstrated that GPF increased the viability of LPS-induced pneumonia cells. ELISA demonstrated that GPF reduced LPS-induced oxidative stress and inflammation in pneumonia cells. The results confirmed that GPF could serve as a promising drug for treating pediatric pneumonia. Multiple biological activities of GPF have been unraveled in several types of diseases. GPF attenuated osteoclastogenesis as well as relieved osteoporosis by suppressing MAPKs/c-Fos/NFATc1 pathway. GPF regulated growth and metastasis of non-small cell lung cancer (NSCLS) by regulating the AMPK/miR-299-5p/ATF2 pathway. In addition, GPF could protect keratinocytes against oxidative stress-induced cell damage. Similarly, we also discovered that GPF suppressed oxidative stress in pediatric pneumonia. It could also reduce neuroinflammation and oxidative stress induced by cerebral ischemia-reperfusion through activating PI3K/Akt/Nrf2 pathway. Here, GPF also improved the activity of Nrf2 in LPS-treated pneumonia cells, and hence alleviated inflammation and oxidative stress in pediatric pneumonia. However, this precise mechanism requires further study.

Pediatric pneumonia results in lung tissue destruction, neutrophil infiltration, and release of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6 in children. Activated
neutrophils spread out inflammation and injury by producing ROS and proteolytic enzymes.\textsuperscript{25,26}

The present research also revealed that GPF improved the activity of Nrf2 in LPS-induced pneumonic cells. As observed, this pathway plays a critical role in mediating inflammation and oxidative stress in different types of diseases. Several drugs or proteins could affect and control the progression of pediatric pneumonia through this pathway. We assume that the Nrf2 pathway could act as a target for pediatric pneumonia.

To summarize, we established that GPF reduced LPS-induced oxidative stress and inflammation in pneumonia cells. It also improved the activity of Nrf2 in LPS-treated pneumonic cells, and therefore alleviated pediatric pneumonia.

### Competing Interests

The authors stated that there were no conflicts of interest to disclose.

### Ethics Approval

This study did not contain any research involving human participants or animals performed by any of the authors.

### Data Availability

The authors declare that all data supporting the findings of this study are available within the paper and any raw data can be obtained from the corresponding author upon request.

### Author Contribution

Cheng Xu and Lei Song designed the experiments, and Weiyan Zhang conducted the same. Rong Zou analyzed and interpreted the data, and Meijun Zhu prepared the manuscript with contributions from all coauthors.

### References


